Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A

As of June 30, 2026, Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H carries a market capitalization of 431.27B, placing it among publicly traded companies globally. Its enterprise value stands at 387.06B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H's next confirmed earnings release is scheduled for October 27, 2026.

As of June 30, 2026, Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H has 7.45B shares outstanding.

As of June 30, 2026, Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H trades at a trailing price-to-earnings ratio of 37.67. The price-to-sales ratio is 10.45, and the price-to-book ratio stands at 5.79.

As of June 30, 2026, Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H trades at an EV/EBITDA multiple of 31.82 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 10.32 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 31.82 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 387.06B versus a market cap of 431.27B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H maintains a current ratio of 11.68, meaning it holds 11.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.10, indicating conservative leverage, while an interest coverage ratio of 1,835.72 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H posted a return on equity (ROE) of 16.15, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 16.34 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 14.75, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 15.98, useful for judging operating efficiency across full business cycles. The company generates approximately 1.83M in revenue per employee across its workforce of 20,511.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.60 indicates how many times Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H recorded 1.41B in income tax expense. That works out to an effective tax rate of 11.96, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 11.82B, leaving 10.40B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H's stock has declined approximately 39.22% over the past 52 weeks. The 50-day moving average sits at 47.86, while the 200-day moving average is 60.02.

Over the twelve months ended June 30, 2026, Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H generated 37.51B in revenue and converted that into 10.40B in net income, yielding earnings per share of 1.53. EBITDA reached 12.17B, while operating income came in at 10.85B.

As of June 30, 2026, Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H holds 44.89B in cash and equivalents against 78.57M in total debt, resulting in a net debt position of -44.77B. Total book value stands at 74.51B, with working capital of 52.43B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H posted a gross margin of 86.67, reflecting its pricing power and cost economics. The operating margin of 28.93 and net profit margin of 27.74 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H paid dividends of 0.00 per share. The dividend payout ratio of 0.11 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -1.82, meaning Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H has an Altman Z-Score of 41.55, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.